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ABSTRAK 
Tajuk : Perbandingan d.iantara 'fentanyl' dan 'esmolol' dalam mengbalang 
kenaikan tekanan intrakranial ketika penyedutan tiub trakea terhadap pesakit 
yang mengalami kecederaan kepala yang teruk. 
Latarbelakang 
Rawatan utama bagi pesakit yang mengalami kecederaan kepala yang teruk ialah 
menghalang kenaikan tekanan intrakranial eli samping memastikan perfusi otak dalam 
keadaan yang baik. Proses perawatan boleh menyebabkan kenaikan tekanan intrakranial. 
Sebagai contohnya, penyedutan di dalam tiub trakea menyebabkan kenaikan tekanan 
intrakranial setiap kali penyedutan dijalankan. Fentany merupakan sejenis ubat untuk 
menahan sakit ( opiod). Ia diberi kepada pesakit sebelum penyedutan dijalankan untuk 
menghalang kenaikan tekanan intrakranial dari rangsangan penyedutan itu. Esmolol 
merupakan sejenis ubat yang bertindak di reseptor betal-adrenergik. Ia digunakan untuk: 
menghalang tindakbalas k.ardiovascular ketik.a proses laryngoscopi dan juga digunakan 
sebagai pengawal tekanan dan peredaran darah. 
Objektif 
Matlamat kajian ini adalah untuk melihat keberkesanan fentanyl dan esmolol terhadap 
perubahan tekanan intrakranial, tekanan perfusi otak, tekanan darah dan denyutanjantung 
IX 
ketika penyedutan dijalankan kepada pesakit yang mengalami kecederaan kepala yang 
teruk dan membandingkan kesan kawalan fentanyl dan esmolol terhadap tekanan 
intracranial ketika penyedutan itu dijalankan. 
Tataeara 
Seramai enam puluh dua orang pesakit yang dimasukkan ke unit rawatan rapi neuro 
dengan tahap Glasgow Coma Scale 8 dan kurang daripadanya, dipasang alat untuk 
mengukur tekanan intrakranial dan diberi bantuan pernafasan dengan mekanikal 
ventilator. Mereka secara rawak diberi samada fentanyl (lmcg/kg) atau esmolol (lmg/kg) 
sebelum penyedutan tiub trakea dijalankan. Tekanan darah arteri, purata tekanan darah 
arteri, denyutan jantung, tekanan intrakranial, tekanan perfusi otak, kandungan gas di 
dalam darah arteri dan indeks bispektral direkodkan sebelum penyedutan, selepas 
penyedutan, 5 minit, 10 minit dan 15 minit selepas penyedutan. 
Keputusan 
Fentanyl dan esmolol menunjukkan tiada perbezaan yang signifikan pada intracranial 
pressure dan bispectral index ketika penyedutan tiub trakea dijalankan. Perbezaan yang 
signifikan hanya didapati pada tekanan darah purata, tekanan perfusi otak dan denyutan 
jantung. 
Kesimpulan 
Kami merumuskan bahawa pesakit yang mengalami kecederaan kepala yang teruk, 
sekiranya mereka diberi ubat sedatif yang secukupnya dan mempunyai tekanan 
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intrakranial yang normal, penggunaan fentanyl atau esmolol dalam menghalang kenaikan 
tekanan intrakranial tidak: menunjukan sebarang perbezaan. Walau bagaimana pun 
esmolol (lmg/kg) lebih baik berbanding fentanyl (lmcg/kg) dalam mengawal tekanan 
darah dan tekanan perfusi otak ketika proses itu. 
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ABSTRACT 
TITLE: A Comparison Between Fentanyl And Esmolol In Preventing Increases In 
Intracranial Pressure During Endotracheal Suction In Severe Head Injury Patient. 
Background 
Preventing increases m intracranial pressure while maintaining adequate cerebral 
perfusion is a primary goal in the treatment of adults with a severe head injury. Routine 
nursing interventions can trigger reactive intracranial hypertension. For example, 
endotracheal suctioning causes a progressive increase in intracranial pressure with each 
insertion of the suctioning catheter. In current practice fentanyl, a rapid onset opiod was 
given before suctioning to blunt responses to noxious stimuli. Esmolol, a rapid- onset and 
short-acting selective betal-adrenergic receptor antagonist is utilized to attenuate the 
cardiovascular response to laryngoscopy and as an adjWlct to controlled circulatory 
techniques. 
Objectives 
The goals of this study are to observe the effect of fentanyl and esmolol on the changes in 
intracranial pressure, cerebral perfusion pressure, mean arterial pressure and heart rate 
responses during endotracheal suctioning in adults with severe head injuries and to 
compare the effect of fentanyl and esmolol in preventing increase in intracranial pressure 
during endotracheal suction. 
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Methods 
Sixty two patients who are admitted to neurointensive care unit with Glasgow Coma 
Scale (GCS) of 8 and less, with intracranial pressure monitoring in place and 
mechanically ventilated. The patients were then randomly received either esmolol 
(lmglkg) or fentanyl (lmcglkg) before endotracheal suction. Arterial blood pressure 
(ABP), mean arterial pressure (MAP)~ heart rate (HR), intracranial pressure (ICP)~ 
cerebral perfusion pressure (CPP)~ arterial blood gases (ABG) and bispectral index (BIS) 
were recorded at baseline, immediately after and 5 minutes, 10 minutes and 15 minutes 
after endotracheal suctioning. 
Results 
There were no significant difference in ICP and BIS in patients who are given either 
fentanyl or esmolol in preventing a raise in intracranial pressure during endotracheal 
suctioning. A significant difference was seen in mean arterial pressure, cerebral perfusion 
pressure and heart rate. 
Conclusion 
We conclude that in patients with severe head injury who are well sedated and had a 
normal intracranial pressure, the used of fentanyl or esmolol in preventing a raise in 
intracranial pressure during endotracheal suction has no advantage. However, esmolol (1 
mglkg) is better than fentanyl ( 1 meg/kg) in control mean arterial pressure and cerebral 
perfusion pressure during endotracheal suctioning. 
Xlll 
CHAPTER 1: INTRODUCTION 
1.1 Introduction 
Severe head injury is defined as head trauma or injury with Glasgow Coma Score (GCS) of 
8 or less. Severe head injury is a significant cause of death and disability and associated 
with raised intracranial pressure (ICP) in 50-75% of patients. Raised ICP is defined as 
intracranial pressure greater than 20 mmHg. An ICP more than 20 mm Hg has been found 
to be a powerful predictor of poor neurological outcome in adults with severe head injury 
(Becker et al, 1977, Marshall et al, 1979). For that reason, intracranial pressure is the main 
parameter monitored in head-injured patients. It is a reflection of the relationship between 
alterations in craniospinal volume and the ability of the craniospinal axis to accommodate 
added volume. ICP normally increases with activities such as endotracheal or oral 
suctioning, coughing and painful stimuli, and does not warrant intervention unless it does 
not return to baseline within about 5 minutes. 
Almost all severe head injury patients are mechanically ventilated. Routine nursing 
procedure such as endotracheal suction is frequently performed to remove pulmonary 
secretions and maintain an airway patency. This is a potentially dangerous procedure in 
patients with head injury because it can increase intracranial pressure. In most patients, 
elevations in intracranial pressure are transient and the pressure returns to the baseline 
level within minutes. In some patients, intracranial pressure may take more than 15 
minutes to return to baseline. This need interventions such as drainage of cerebrospinal 
fluid and administration 
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of osmotic diuretics, sedatives or paralyzing agents to reduce the pressure to less than 20 
mm Hg. Gemma et al, (2002) found that in well-sedated patients, endotracheal suctioning 
caused an increase in intracranial pressure~ cerebral perfusion pressure ( CPP) and jugular 
oxygen saturation (Sj02). Brucia et al, (1996) found that tracheal stimulation during 
suction catheter insertion initiates both cerebrovascular responses such as ICP and CPP 
and systemic vascular response such as mean arterial pressure (MAP). For such a reasons, 
several modalities have been advocated to reduce secondary brain damage such as use of 
sedation and muscle relaxant or lignocaine administration before endotracheal suction 
(Donegan et al, 1980). 
Although opiates such as morphine sulfate and fentanyl citrate may prevent increases in 
intracranial pressure, reports of the efficacy of opiates in preventing increases in 
intracranial pressure in response to endoctracheal suctioning are inconsistent. As 
commonly practiced in this institution, intravenous (IV) fentanyl (0.5 - lmcg/kg) was 
given before suctioning to blunt response to noxious stimuli. White et al, (1982) found that 
administration of fentanyl did not attenuate the increase in intracranial pressure that 
occurred with endotracheal suctioning in an animal model. Lauer et al, ( 1997) suggests that 
when opioids are titrated in head-injured patients, worsening intracranial pressure can be 
avoided. Schregel et al, (1994) concluded that opioids are often beneficial and not 
generally contraindicated for patients with cerebral diseases and compromised intracranial 
compliance. 
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Chung et al, (1992) found that the combination of a low dose of fentanyl and esmolol 
provides an alternative to a higher dose of fentanyl for blunting the haemodynamic 
responses to laryngoscopy and tracheal intubation during rapid-seque~ce induction in 
healthy patients. Intravenous esmolol (1.0 - 1.5 mglkg) is utilized to attenuate the 
cardiovascular response to laryngoscopy, to treat supraventricular tachycardias and as an 
adjunct to controlled circulatory techniques. Subsequent experience with the drug has 
produced evidence for the efficacy of esmolol as anaesthetic adjunct Menigaux et al, 
(2002) reported that esmolol not only attenuated haemodynamic and somatic responses to 
laryngoscopy and orotracheal intubation, but also prevented bispectral index (BIS) arousal 
reactions in patients anaesthetized with propofol. Bagshaw et al, (1995) reported that 
esmolol proved to be a satisfactory substitute for narcotics in a nitrous oxide/relaxant 
anaesthetic technique and was associated with shorter times to ambulation and discharge. 
Bensky et al, (2000) showed that small doses of esmolol (0.4mg/kg) may block the 
increases in heart rate and blood pressure resulting from laryngoscopy and intubation .. 
1.2 Objectives of the study 
The goals of this study are to observe the effect of fentanyl and esmolol on the changes in 
intracranial pressure, cerebral perfusion pressure, mean arterial pressure, heart rate and 
bispectral index responses during endotracheal suc1ioning in adults with severe head 
injuries and to compare the effects of fentanyl and esmolol in preventing increase in 
intracmnial pressure during endotracheal suctioning. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Intracranial pressure 
2.1.1 Physiology 
Intracranial pressme is a term applied to the pressure inside the cranial vault relative to 
atmospheric pressure. Normal intracranial pressure in adults is between 5 mm Hg and 15 
mm Hg. Intracranial pressure above 15 mm Hg is abnormal. Increased ICP has been 
defined as a pressure more than 20 mm. Hg persisting for 5 min (Bullock et al, 2000). 
Lundberg (1960) suggested that mean levels above 20 mmHg are moderately elevated and 
sustained levels above 40 mmHg are severely increased. Miller et al, (1981) reported that 
the mortality rate increased from 18 to 92 % and that the frequency of good outcomes 
decreased from 74 to 3% when cases of normal ICP were compared with those of 
intracranial hypertension more than 20 mm Hg. ICP is not a static state, but is influenced 
by several factors. The recording of ICP shows 2 forms of pressure fluctuations. There is a 
rise with cardiac systole (due to distention of intracranial arteriolar tree) and a slower 
change in pressure with respiratio~ falling with each inspiration and rising with expiration. 
Straining and compression of neck veins can also cause a sudden, considerable rise in 
pressure. 
The conception of the cramwn acting as a near rigid container of incompressible 
substances in the form of brain, blood and cerebrospinal fluid ( CSF) in known as the 
Monro Kellie doctrine. The composition of the intracranial contents and their volumes (%) 
are as follows: 
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Brain tissue/interstitial water 85% 
Blood volume 10% · 
Cerebrospinal fluid (CSF) 5% 
Intracranial pressure is determined by the interaction of the brain mass, cerebral blood 
volume and cerebrospinal fluid volume. As the Munro-Kellie doctrine dictates that a 
change in any one of these compartments must be counteracted by an opposite change in 
another compartment in order to maintain the same ICP. While volume of the brain (about 
1400ml in an adult) being constant, intracranial pressure is a result of at least 2 factors: 
a) CSF which is constantly secreted and after circulating absorbed at an equal rate. 
CSF circulation is slow (500 to 700 mllday). At a given time the cranium contains 
75 mlofCSF. 
b) Intracranial circulation of blood which is about 1000 litres per day delivered at a 
pressure of 100 mmHg and at a given time, the craniwn contains 75 ml of blood. 
In the presence ofhaematoma or development of hydrocephalus the initial compensation is 
by displacement of blood and CSF from the vault, the brain volume remaining unchanged. 
However, once cerebral oedema develops, any further increase in the ICP results in the 
failure of the compensatocy mechanisms with ensuing sharp rise in ICP. Once this state is 
reached, any minor increase in any one of the three compartments will lead to dramatic 
increase in ICP with a corresponding drop in the cerebral blood flow. 
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2.1.2 Control of intracranial pressure 
a) Volume Buffering ( Pressure- Volume ·Relationship) 
10 1-~1 ...... _..---~2...---
Intracranial volume (ml) 
Figure 2.1 Intracranial Pressure- Volume Curve 
(Gupta A.K and Summors A. C. 200 l.Notes in Neuroanaesthesia and Critical Care. 
Greenwich Medical Media Limited.6,24) 
During slow increase in volume in a continuous mode between points 1 and 2, the ICP 
raises to a plateau level at which the increase level of CSF absorption keeps pace with the 
increase in volume. At point 2, further increases in volume cause a slight rise in ICP. 
6 
Intermittent expansion causes only a transient rise in ICP at first When sufficient CSF bas 
been absorbed to accommodate the volume the ICP returns to normal. As volume increase, 
there is a steady decline in compliance which increase the ICP even more (point 3) until a 
small rise in voiume is associated with a marked rise in ICP causing a fall in the perfusion 
pressure and ultimately cerebml ischaemia (between points 3 and 4). The ICP finally rises 
to the level of arterial pressure which itself begins to increase, accompanied by bradycardia 
or other disturbances of heart rhythm (Cushing response). This is accompanied by 
dilatation of small pial arteries and some slowing of venous flow which is followed by 
pulsatile venous flow. The rise in ICP to the level of systemic arterial pressure extinguishes 
cerebral circulation which will restart only if arterial pressure rises sufficiently beyond the 
ICP to restore CBF. If it fails, brain death occurs. In patients with parenchymal lesion 
(tumor, hematoma and contusion), because of the shift of brain and disturbed auto 
regulation, CBF may by compromised with relatively low levels ofiCP. 
The raise in ICP disturbs brain function by: 
i. Reduction in CBF 
u. Transtentorial or foramen magnum herniation resulting in selective compression 
and ischaemia in the brain stem. 
Transtentorial herniation with brainstem compression can lead to clinical 
deterioration even with adequate CBF. A temporal mass may cause uncal 
herniation without mised ICP. Similarly a frontal mass can cause axial distortion to 
impair brainstem perfusion. 
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b) Cerebrospinal Fluid 
The reduction of the volume from one compartment as a result of an increase in another 
compartment is known as 'spatial compensation'. CSF plays the biggest role in spatial 
compensation. As a space occupying lesion expands, it will cause progressive reduction of 
the CSF space (reduced size of the ventricles/basal cistens). Rapidly growing masses (e.g. 
haematoma) exhaust spatial compensation quickly resulting in a rapid rise ofiCP. 
c) Cerebral Blood Volume (CBV) 
Most of the intracranial blood volume is contained in the venous sinuses and pial vems. 
This acts as a buffer in the event of raised ICP. Factors affecting CBV include: 
1. Venous distension - from jugular venous obstructio~ increased intrathoracic 
pressure, raised central venous pressure, head down tilt and vasodilators. 
n. PaC02- Both cerebral blood flow (CBF) and CBV increase with raised PaC02 
(Figure 2.2), but the CBV response curve is flatter than the CBF curve. A reduction 
in PaC02 from 40 mm Hg to 20 mm Hg results in a 65% reduction in CBF but 
only a 28% reduction in CBV (2.8 mlllOOg). This small change in intracranial 
volume will have a significant reduction in ICP in the presence of intracranial 
hypertension because the system operates on the steep part of the pressure volume 
curve. 
iii. Pa02 - Cerebral vasodilatation occurs with hypoxia resulting in a rise in CBV. 
There is evidence that hyperoxia causes vasoconstriction although there is no 
human evidence to suggest this is clinically significant. 
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Figure 2.2 Relationship of Cerebral blood flow and cerebral blood volume with 
changes in arterial carbon dioxide. 
(Gupta AK and Summors AC. 200l.Notes in Neuroanaesthesia and Critical Care. 
Greenwich Medical Media Limited 6,24) 
tv. Flow-metabolism coupling- Increased metabolic demand increases CBF, CBV and 
ICP. 
v. Autoregulation - A fall in MAP can lead to a decrease in cerebrovascular tone 
causing cerebral vasodilatation and increase in CBV within limits. 
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2.1.3 Cerebral blood flow (CBF) 
The brain accounts for only 2% of total body-weight, yet its blood flow represents 15% of 
resting cardiac output and uses 20% total amount of oxygen consumed Cerebral Blood 
Flow (CBF) in humans averages approximately 50 mL/lOOg of brain tissue per minute. 
Irreversible neuronal damage occurs if CBF drops to less than 18 mL/1 00 g of brain tissue 
per minute for a prolonged period of time, (Heiss et al, 1983). CBF is equal to the cerebral 
perfusion pressure (CPP), which is defined as the difference between the mean arterial 
blood pressure (MAP) and the ICP, divided by the cerebral vascular resistance. Because 
the CBF is difficult to measure clinically, the CPP is used as a guide to assessing the 
adequacy of cerebral perfusion. 
CPP =MAP- (ICP + CVP) 
where MAP = Mean Arterial Blood Pressure, CVP = Central Venous Pressure 
Normal human values for CPP are between 70 mm Hg and 100 mm Hg. However as a 
result of autoregulation, CBF remains relatively constant when CPP is between 40 mm Hg 
and 140 mm Hg, (Kelly et al, 1993). Cerebrovascular autoregulatory mechanisms are 
disrupted following head trauma, with CBF dependent largely on the CPP. Any factor that 
decreases MAP or increases the ICP or jugular venous pressure decreases CPP and 
therefore CBF. Obrist et al, (1984) approximated that one half of patients with severe head 
injury had a variable degree of autoregulation impairment. 
This auto regulation can divide into: 
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a Myogenic regulation - suggests direct reaction of the cerebral arterial smooth 
muscles to the stretch. 
b. The humoral regulation - involves regulations by the direct effect of by- products 
of metabolism. 
c. Neurogenic regulation- autonomic nervous system mainly affects the large cerebral 
vessels. B-1 adrenergic stimulation results in vasodilation whereas a-2 adrenergic 
stimulation causes vasoconstriction. 
The ICP influences the CBF through the cerebral perfusion pressure (CPP) which is the 
difference between mean arterial pressure (MAP) and ICP. Raise in ICP would lead to a 
fall in CPP and every effort should be taken to maintain the CPP to 50 mm Hg or more 
during treatment of raised ICP. 
2.1.4 Clinical features of raised ICP 
Raised ICP causes arterial hypertension, bradycardia (Cushing's response) and respiratory 
changes. It is accepted that hypertension and bradycardia are due to ischaemia or pressure 
on the brainstem. There is also a suggestion that they could be due to removal of 
supratentorial inhibition of brainstem vasopressor centers due to cerebral ischaemia and 
that bradycardia is independent of the rise in blood pressure. 
The respiratory changes depend on the level of brainstem involved The midbrain 
involvement result in Chyne·Stokes respiration. When midbrain and pons are involved, 
there is sustained hyperventilation. There is rapid and shallow respiration when upper 
medulla involvement with ataxic breathing in the final stages. 
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Pulmonary edema seems to be due to increased sympathetic activity as a result of the 
effects of raised ICP on the hypothalamus, medulla or cervical spinal cord. 
2.1.5 ICP monitoring 
ICP monitoring is most often used in head trauma in the following situations: 
a) GCS less than 8 
b) Drowsy with CT findings (operative or non operative) 
c) Post - operation hematoma evacuation 
d) High risk patients : 
1. Above 40 yrs. 
u. LowBP 
iii. Those who require ventilation. 
Non invasive methods ofiCP monitoring: 
a) Clinical deterioration in neurological status is widely considered as sign of 
increased ICP. Bradycardia, increased pulse pressure, pupillary dilation are 
normally accepted as signs of increased ICP. 
b) Transcranial doppler, tympanic membrane displacement, and ultrasound 'time of 
flight' techniques have been advocated. Several devices have been described for 
measuring ICP through open fontanelles. Ladd fiber optic system bas been used 
extra cutaneously. 
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c) Manual feeling of the craniotomy flap or skull defect, if any, may give a clue to the 
ICP. 
Invasive methods ofiCP monitoring: 
a) Intraventricular catheter is a 'Gold standard' of ICP measurement (The Brain 
Trauma Foundation, 2000). Advantage is the potential for draining CSF 
therapeutically. Disadvantages are include high bacterial colonisation rates 
(positive CSF or catheter tip culture, 1-5% after 3 days), difficult placement, injury 
to brain tissue and potential for leaks/blocks in the system. Guyot et al, ( 1998) 
found that ventriculostomy had more complications and infections than 
intraparenchymatous ICP devices (12.4% vs 1.2%) and if complications were 
present, the Glasgow Outcome Score was worse. 
b) Other most commonly used devices are the hollow screw and bolt devices, and the 
sub dural catheter. Richmond screw and Becker bolt are used extradurally. A fluid 
filled catheter in the subdural space, connected to arterial pressure monitoring 
system is cost effective and serves the purpose adequately. 
c) Ladd device is currently in wide use. It employs a fibre optic system to detect the 
distortion of a tiny mirror within with balloon system. It can be used in the 
subdural, extradural and even extra cutaneously. 
d) A mechanically coupled surface monitoring device is the 'cardio search pneumatic 
sensor' used subdurally or extradurally. These systems are not widely used. 
e) Electronic devices (Camino & Galtesh design) are getting popular. 
Intraparenchymal probes, the measured pressure may be compartmentalized and 
13 
not necessarily representative of real ICP. In addition to ICP monitoring, modern 
intraparenchymal sensors help study the chemical environment of the site of 
pathology. 
f) Fully implantable devices are valuable in a small group who requires long term ICP 
monitoring for brain tumors, hydrocephalus or other chronic brain diseases. 
Cosmon intrcranial pressure telesensor can be implanted as a part of shunt system. 
Ommaya reservoir is an alternative which can be punctured & CSF pressure 
readings are obtained. 
2.1.6 Benefits of ICP monitoring 
Intracranial pressure measurement plays an important role in the management of patients 
with head injury and neurosurgical patients. Several studies have shown that under 
conditions of aggressive ICP management, the probability of a good outcome is inversely 
proportional to the maximum ICP and the percentage of the time spent at levels of more 
than 20 mm Hg. The association between the severity of intracranial hypertension and poor 
outcome after severe head injury is well recognized. Saul and Ducker, (1981) reported a 
69% mortality rate in patients with an ICP greater than 25 mm Hg compared with that of 
15% in those in whom the ICP remained less than 25 mm Hg. Monitoring is the only 
means by which therapy can be selectively employed and the effectiveness of therapy can 
be accumtely studied. 
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2.1. 7 Treatment of increased ICP 
There is no doubt the best treatment for increastd ICP is the removal of the causative 
lesion such as tumors, hydrocephalus, and hematomas. Treatment is aimed at preventing 
the secondary events. Current data suggest that an upper threshold of 20-25 nun Hg should 
be used to initiate intervention to reduce ICP. (The Brain Trauma Foundation, 2000). 
The following therapeutic measures are available. 
a) First line of management: 
General measures of treatment essentially making the patient comfortable and ABC 
of trawna management are effectively instituted. Careful attention to nutrition and 
electrolytes, bladder and bowel functions and appropriate treatment of infections 
are instituted promptly. Adequate analgesia it is a must even in unconscious 
patients. 
b) Second line of management 
1. Induced cerebral vasoconstriction- Hyperventilatio~ hyper baric 02, hypothermia 
11. Osmotherapy- Mannitol, glycerol ,urea 
111. Anesthetic agents - Barbiturates, gamma hydroxybutyrate, Etomidate, 
tv. Surgical decompression 
Hyperventilation aims at keeping the pC02 down to 30-25 mm Hg so that CBF falls and 
cerebral blood volume is reduced and thereby reducing the ICP. Prolonged 
hyperventilation should be avoided and becomes ineffective after about 24 hours. In 
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addition it causes hypotension due to decreased venous return. It is claimed a pC02 under 
20 mm Hg results in ischemia, although there is no experimental proof. The present trend 
is to maintain normal ventilation with pC02 in the range of 30 - 35 mm.Hg. When there is 
clinical deterioration such as pupillary dilatation or widened pulse pressure, 
hyperventilation may be instituted until the ICP comes down. 
Hyperbaric oxygen and hypothermia are still in the experimental stage. They basically 
induce cerebral vasoconstriction and reduce the cerebral blood volume and the ICP. 
Osmotherapy is useful in the cytotoxic edema stage, when capillary permeability is intact, 
by increasing the serum osmolality. Mannitol is still the most common osmotic diuretic 
used to reduce to ICP. It may also act as a free radical scavenger. Glycerol and urea are 
hardly used these days. Several theories have been advanced concerning the mechanism by 
which mannitol reduces ICP. 
a) It increases the erythrocyte flexibility, which decreases blood viscosity and causes a 
reflex vasoconstriction that reduces cerebral blood volume and decreases ICP and 
may reduce CSF production by the choroids plexus. In small doses it protects the 
brain from ischemic insults due to increased erythrocyte flexibility. 
b) The diuretic effect is mainly around the lesion, where blood brain barrier integrity 
is impaired and there is no significant effect on normal brain. Intraaxial lesions 
respond better than extra axial lesions. 
c) Another theory is mannitol withdraws water across the ependyma of the ventricles 
in a manner analogous to that produced by ventricular drainage. 
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Barbiturates can lower the ICP when other measures fail but have no prophylactic value. 
They inhibit free radical mediated lipid peroxidation and suppress cerebral metabolism; 
cerebral metabolic requirements and thereby cerebral blood volume are reduced resulting 
in the reduction ofiCP. 
Decompressive craniectomy such as sub temporal decompression are recommended only 
in highly selected patients. Herniation of brain through defect, cause further injury, further 
edema and further increased ICP. But in occasional cases, when every other measure has 
failed, such decompression craniectomy may be justified 
2.2 FENTANYL 
2.2.1 Classification 
Fentanyl citrate is chemically identified as N-(1-phenethyl-4-piperidyl) propionanilide 
citrate with a molecular weight of 528.60. The empirical formula is C22H2sN20·C~07• 
Figure 2.3 Chemical Structure of Fentanyl 
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2.2.2 Indications and usage 
a) Analgesic action of short duration dUring the anesthetic periods, premedication, 
induction and maintenance, and in the immediate postoperative period. 
b) Use as a narcotic analgesic supplement in regional anesthesia. 
c) Administration with a neuroleptic such as droperidol injection as an anesthetic 
premedication, for the induction of anesthesia and as an adjunct in the maintenance 
of general and regional anesthesia. 
d) Use as an anesthetic agent with oxygen in selected high risk patients, such as those 
undergoing open heart surgery or certain complicated neurological or orthopedic 
procedures. 
2.2.3 Presentation 
Each ml contains fentanyl citrate equivalent to 50 meg of fentanyl base, adjusted to pH 
4.0-7.5 with sodium hydroxide. It is clear, colourless, isotonic and preservative free 
solution. 
2.2.4 Clinical pharmacology 
Fentanyl citrate is a narcotic analgesic. A dose of 100 meg is approximately equivalent in 
analgesic activity to 10 mg of morphine or 75 mg of meperidine. The principal actions of 
therapeutic value are analgesia and sedation. It is highly selective mu agonist. Fentanyl had 
little hypnotic or sedative activity and miosis due to stimulation of Edinger-Westphal 
nuc1~us. Non-epileptic myoclonic movements with no epileptiform electroencaphalogram 
(EEG) patterns are seen in patient who are given fentanyl (Maninen et al, 1997). Opiods 
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are known to inhibit the release of different neurotransmitters in the central nervous system 
which may be expected to decrease cerebral metabolism (Snyder, 1978). Milde et al, 
( 1989), studied in dogs the effect of fentanyl upon CBF and CMR02 and found a small 
decrese in C:MR02 and a 14% increase in CBF. Alterations in respiratory rate, ventilatory 
response to hypoxia and hypercapnia and alveolar ventilation, associated with narcotic 
analgesics, may last longer than the analgesic effect As the dose of narcotic is increased, 
the decrease in pulmonary exchange becomes greater. Large doses may produce apnea and 
chest wall rigidity (wooden chest phenomenan). Fentanyl appears to have less emetic 
activity than either morphine or meperidine. Histamine assays and skin wheal testing in 
man, indicate that clinically significant histamine release rarely occurs with fentanyl. 
Fentanyl preserves cardiac stability and blunts stress ... related hormonal changes at higher 
doses. Bradycardia of vagal origin is the most significant cardiovascular effect noted. High 
doses obtund metabolic stress response to surgery. Fentanyl decrease gastrointestinal 
motility and gastric secretions but it increase ureter, detrussor and vesicular sphincter tone. 
The pharmacokinetics of fentanyl can be described as a three...compartment model, with a 
distribution time of 1. 7 minutes, redistribution of 13 minutes and a tenninal elimination 
half-life of 219 minutes. The volume of distribution for fentanyl is 4 Llkg. Fentanyl has 
81% - 94% protein binding in plasma. It more lipid soluble than morphine therefore 
crosses the blood brain barrier faster, resulting in a more rapid onset. It short duration of 
action is due to redistribution rather than metabolism. It accumulates in skeletal muscle 
and fat and is released slowly into the blood The lungs also serve as a large, inactive 
storage site with an estimated 75% of the initial fentanyl dose undergoing first-pass 
pulmonary uptake (Roerig et al, 1987). Secondary peak of fentanyl is a result of washout 
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of opioid from the lungs as ventilation to perfusion relationships are reestablished in the 
postoperative period. This increases the plasma levels of opioid in the circulation and 
causes respiratory depression. As the duration of continuous infusion of fentanyl increases 
beyond 2 hours~ the context-sensitive half-time become greater. 1bis reflects saturation of 
inactive tissue sites with fentanyl during prolonged infusions and return from peripheral 
comPartments to the plasma. 
Fentanyl is metabolized rapidly in the liver by N-dealkylation to norfentanyl then 
hydroxylated to hydroxypropionyl derivatives. Approximately 75% of an intravenous dose 
is released in urine, mostly as metabolites with less than 10% representing the unchanged 
drug. Approximately 9% of the dose is recovered in the feces~ primarily as metabolites. 
The onset of action of fentanyl is almost immediate when the drug is given intravenously; 
however, the maximal analgesic and respiratory depressant effect may not be noted for 
several minutes. The usual duration of action of the analgesic effect is 30-60 minutes after 
a single N dose of up to 100 meg. Following intramuscular (IM) administration, the onset 
of action is from 7-8 minutes, and the duration of action is 1 ... 2 hours. 
2.2.5 Dosage and administration 
Dosage should be individualized. Factors to be considered in determining the dose are age, 
body weight, physical status, underlying pathological condition, use of other drugs, type of 
anesthesia to be used and the surgical procedure involved. 
a) Premedication 
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A dose of 50-100 meg may be administered intramuscularly 30-60 minutes prior to 
surgery. 
b) Analgesic supplement to general anaesthesia 
Dose ranges from 1- 50 meg/kg. A dose of 1- 2 meg/kg is usually useful in most cases. 
Dosages of higher ranges in particular 20 - 50 meg/kg requires post operative ventilation 
and observation in view of the possibility of extended post operative respiratory 
depression. 
c) Use as anaesthetic agent 
Dose of 50 - 100 meg/kg help attenuates surgical stress. It is used in cardiac surgery. 
d) Adjunct to Regional Anesthesia 
A dose of50-100 meg may be administered intramuscularly or slowly intravenously, over 
1-2 minutes, when additional analgesia is required. 
e) Postoperatively 
A range of 50-100 meg may be administered intramuscularly for the control of pain, 
tachypnea and emergence delirium. The dose may be repeated in 1-2 hours as needed. 
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2.2.6 Contraindieations 
Fentanyl citrate injection is contraindicated m patients with known intolerance to the drug 
or other opioid agonists and patient with monoamine oxidase (MAO ) inhibitor as it may 
precipitate hypertensive crisis. 
2.2. 7 Precautions 
Elevated blood pressure, with and without pre-existing hypertension, has been reported 
following administration of fentanyl citrate combined with droperidol. This might be due 
to unexplained alterations in sympathetic activity following large doses however it is also 
frequently attributed to anesthetic and surgical stimulation during light anesthesia. 
Fentanyl may produce bradycardia, which may be treated with atropine. It needs to be used 
with caution in patients with cardiac bradycardias. 
In severe head injury patients, who may be susceptible to respiratory depression, fentanyl 
should be used with caution. In addition, fentanyl may obscure the clinical course of 
patients with head injury. 
2.2.8 Interactions 
Other central nervous system depressant drugs (e. g. barbiturates, tranquilizers, narcotics 
and general anesthetics) will have additive or potentiating effects with fentanyl. The opioid 
- benzodiazepine combination displays marked synergism with respect to hypnosis and 
depression of ventilation (Vinik et al, 1989). When patients have received such drugs, the 
dose of fentanyl required will be less than usual. 
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2.2.9 Adverse reactions 
The most common serious adverse reactions reported to occur with fentanyl are respiratory 
depression, apnea, rigidity, and bradycardia. If these remain untreated respiratory arrest, 
circulatory depression or cardiac arrest will occur. Other adverse reactions that have been 
reported are hypertension, hypotension, dizziness, blurred vision, nausea, emesis, 
diaphoresis, pruritus, urticaria, laryngospasm, anaphylaxis and secondary rebound 
respiratory depression. 
2.3 ESMOLOL 
2.3.1 Classification 
The chemical name for esmolol hydrochloride is (±)-methyl p-[2-hydroxy-3-
(isopropylamino )propoxy ]hydrocinnamate hydrochloride. Esmolol hydrochloride has the 
empirical formula CtJi26N04Cl and a molecular weight of 331.8. It has one asymmetric 
center and exists as an enantiomeric pair. Esmolol hydrochloride injection is a clear, 
colourless to light yellow, sterile and nonpyrogenic solution. 
Figure 2.4 Chemical Structure of Esmolol 
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2.3.2 Indications and usage 
a) trea1ment of supraventricular tachycardia -
b) intraoperative and postoperative tachycardia and hypertension ( at induction, 
tracheal intubation, during surgery or emergence from anaesthesia ) 
c) myocardial infarction 
2.3.3 Clinical pharmacology 
Esmolol is a befat·selective (cardioselective) adrenergic receptor blocking agent with rapid 
onset, a very short duration of action (Wiest 1995), and no significant intrinsic 
sympathomimetic or membrane stabilizing activity at therapeutic dosages. Effects begin in 
2 minutes and peak in 5 minutes, and the elimination half-life is 9 minutes. Esmolol 
inhibits the betat receptors located chiefly in cardiac muscle, but this preferential effect is 
not absolute and at higher doses it begins to inhibit beta2 receptors located chiefly in the 
bronchial and vascular musculature. 
Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases 
in the cytosol of red blood cells. Total body clearance in man was found to be about 20 
L/k:glh, which is greater than cardiac output; thus the metabolism of esmolol is not limited 
by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or 
renal blood flow. Esmolol has a rapid distribution half-life of about 2 minutes and an 
elimination half-life of about 9 minutes. Heart rate reduction begins more quickly than 
blood pressure reduction. (Ornstein et al, 1995). 
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